RHYTHM PHARMACEUTICALS INC. - COMMON STOCK

Rhythm Pharmaceuticals Announces First Patients Dosed in Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 in Hypothalamic Obesity

23 يوليو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024

23 يوليو 2024 06:30:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

11 يوليو 2024 15:01:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer

08 يوليو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients between 2 and 6 years old with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency

28 يونيو 2024 07:00:14 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

11 يونيو 2024 15:01:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024

03 يونيو 2024 15:02:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference

03 يونيو 2024 07:02:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome

22 مايو 2024 03:00:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

09 مايو 2024 15:01:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update

07 مايو 2024 06:00:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting

06 مايو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology

29 أبريل 2024 17:30:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024

24 أبريل 2024 15:01:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

16 أبريل 2024 15:01:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing

01 أبريل 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist

25 مارس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

11 مارس 2024 15:01:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences

06 مارس 2024 15:01:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan

22 فبراير 2024 06:01:00 بحسب Nasdaq GlobeNewswire